ライフサイエンスコーパス: S1P receptor

1 S1P4 GPCRs as the only functionally relevant S1P receptor.

2 lular signaling mediated by a single type of S1P receptor.

3 dro-S1P, which is active at all cell surface S1P receptors.

4 as a key downstream effector of the BCR and S1P receptors.

5 ates vascular and immune cells by activating S1P receptors.

6 ar face of the third transmembrane domain of S1P receptors.

7 stimulating SK1-dependent transactivation of S1P receptors.

8 720, an immunosuppressant that downmodulates S1P receptors.

9 n, suggesting the requirement for Gi-coupled S1P receptors.

10 finity agonists of at least four of the five S1P receptors.

11 ediated by intracellular S1P, independent of S1P receptors.

12 t can amplify MC responses by binding to its S1P receptors.

13 by approximately 12-fold, independent of the S1P receptors.

14 tic for a family of sphingosine-1-phosphate (S1P) receptors.

15 and interacts with sphingosine-1-phosphate (S1P) receptors.

16 okine receptors and sphingosine-1-phosphate (S1P) receptors.

17 r of the five known sphingosine-1-phosphate (S1P) receptors.

18 ffinity agonist for sphingosine 1-phosphate (S1P) receptors.

19 g as an agonist for sphingosine-1-phosphate (S1P) receptors.

20 a full agonist for sphingosine-1-phosphate (S1P) receptors.

21 ough CCR7, CCR2, and sphingosine-1-phospate (S1P) receptors.

22 phosphorylation of the C-terminal domain of S1P receptor 1 (S1P(1)) at multiple sites, resulting in

23 ell egress from lymphoid organs by acting on S1P receptor 1 (S1P(1)R).

24 eceptors CCR7 and CXCR4 concomitant with low S1P receptor 1 (S1P1) expression.

25 Here, we report that the S1P receptor 1 (S1P1) is expressed in neuroblasts migrat

26 ) deficiency or by selective agonists of the S1P receptor 1 (S1P1), indicating that PAR1 signaling co

27 to FTY720, we saw a significant increase in S1P receptor 1 (S1P1)-expressing CD68+ macrophages in su

28 We found that genetic deletion of the S1P receptor 1 (S1pr1) alone in CD11b(hi) CD206(+) TAMs

29 ingosine-1-phosphate (S1P) signaling via the S1P receptor 1 (S1PR1) in the vascular endothelial cells

30 d by acute treatment with an agonist for the S1P receptor 1 (S1pr1).

31 Only depletion of S1P receptor 1 abrogated the effects of dhS1P and S1P in

32 The S1P receptor 1 agonist SEW2871 rapidly normalized parace

33 SSc fibroblasts, which had reduced levels of S1P receptor 1 and S1P receptor 2 and elevated levels of

34 es with either S1P or a selective agonist of S1P receptor 1 enhanced bacterial colocalisation with LA

35 te (S1P) signaling via the G protein-coupled S1P receptor 1 in these progenitors.

36 In contrast, depletion of either S1P receptor 1 or S1P receptor 2 prevented the effects o

37 sed delayed tumor formation characterized by S1P receptor 1, STAT3 mRNA increase, as well as programm

38 Marginal zone B cells expressed S1P receptors 1 and 3 (S1P(1) and S1P(3), respectively).

39 lipid sphingosine 1-phosphate (S1P), through S1P receptors 1 and 3 (S1P1/S1P3), and VEGF receptor 2 (

40 cells were less evident and eNOS, iNOS, and S1P receptors 1 and 3 were up-regulated in aortas from m

41 nd its derivative, BAF312, which only target S1P receptors 1 and 5, in a mouse model of cryptococcal

42 of sphingosine-1-phosphate (S1P) and targets S1P receptors 1, 3, 4, and 5.

43 dy, we identify the sphingosine 1-phosphate (S1P) receptor 1 (S1P1) as one of the key players that go

44 an immunomodulatory sphingosine-1-phosphate (S1P) receptor 1 (S1P1R) agonist significantly inhibited

45 Functional sphingosine-1-phosphate (S1P) receptor 1 (S1PR1) antagonists, such as FTY720/fing

46 Sphingosine-1-phosphate (S1P) receptor 1 (S1PR1) is critical for lymphocyte egres

47 he egress receptor, sphingosine-1-phosphate (S1P) receptor 1 (S1PR1), was expressed at low levels in

48 tic significance of sphingosine 1-phosphate (S1P) receptors 1, 2, and 3 (ie, S1P1, S1P2, and S1P3), S

49 S1P receptors (1-5) and S1P-metabolizing enzymes were ex

50 e a mechanism by which the G protein-coupled S1P receptor-1 (S1P1) stabilizes the primary vascular ne

51 ase-2 (GRK2) functions in down-regulation of S1P receptor-1 (S1PR1) on blood-exposed lymphocytes.

52 sphate (S1P) and the regulated expression of S1P receptor-1 (S1PR1), we investigated whether the expr

53 ing RNA that targets sphingosine kinase-1 or S1P receptor-1 blocked this protective signaling by APC.

54 S1P receptor-1 is required for lymphocyte egress from th

55 er-disruptive PAR1 pathway, and suggest that S1P receptor-1 mediates protective effects of APC in sys

56 cular functions in other organs, and S1P(1) (S1P receptor-1) modulators including fingolimod show pro

57 The sphingosine 1-phosphate (S1P) receptor-1 (S1P(1)) is required for stabilization o

58 FTY720 or that lack sphingosine-1-phosphate (S1P) receptor-1 (S1P1) in B cells, IgG ASCs are induced

59 he cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1).

60 d organs depends on sphingosine 1-phosphate (S1P) receptor-1 and is thought to occur in response to c

61 Lymphocytes require sphingosine-1-phosphate (S1P) receptor-1 to exit lymphoid organs, but the source(

62 role of endothelial sphingosine 1-phosphate (S1P) receptor-1, a G protein-coupled receptor known to p

63 signaling is a plausible mechanism by which S1P-receptor-1 agonists function as immunosuppressives.

64 l TNF(+) T and Th17 cells and increase their S1P-receptor-1 mediated egress from the intestine and re

65 und that Th17 cells egress from the gut in a S1P-receptor-1-dependent fashion and subsequently migrat

66 the rescue required lymphocyte expression of S1P-receptor-1.

67 the endothelial differentiation gene family (S1P receptors-(1-5)).

68 were abolished following administration of a S1P receptor 2 (S1P2) antagonist or a PI3K inhibitor.

69 ion of Bcr-Abl1 by SK-1/S1P was dependent on S1P receptor 2 (S1P2) signaling, which prevented Bcr-Abl

70 a pharmacologic SphK inhibitor (SKI2), and a S1P receptor 2 (S1PR2) antagonist (JTE013) were used in

71 Conversely, S1P receptor 2 (S1PR2), which antagonizes migration towa

72 ich had reduced levels of S1P receptor 1 and S1P receptor 2 and elevated levels of S1P receptor 3.

73 umors with upregulated sphingosine kinase 1, S1P receptor 2 and epidermal growth factor receptor.

74 BH3 mimetics with either SPHK1 inhibition or S1P receptor 2 antagonism triggered synergistic AML cell

75 trast, depletion of either S1P receptor 1 or S1P receptor 2 prevented the effects of S1P and dhS1P in

76 ociated with reduced survival signaling from S1P receptor 2, resulting in selective downregulation of

77 f FAK and invasion, and this was mediated by S1P receptor 2.

78 phingosine kinase 1 (SphK1) or antagonism of S1P receptors 2 and 4 (S1P2/4).

79 tion was induced in sphingosine 1-phosphate (S1P) receptor 2 (S1P2)-null and wild-type mice by ligati

80 ng mutations in the sphingosine-1-phosphate (S1P) receptor 2 (S1PR2) promoter have been associated wi

81 by combining chemical and genetic probes for S1P receptor 3 (S1P3) we show a critical role for dendri

82 FTY720 triggers MDSCs to release GM-CSF via S1P receptor 3 (S1pr3) through Rho kinase and extracellu

83 have higher expression of LPA receptor 1 and S1P receptor 3 compared with normal kidney.

84 cryptococcosis from the granuloma through a S1P receptor 3-mediated mechanism and support the ration

85 ination (metastasis) of melanoma cells via a S1P receptor 3-mediated mechanism.

86 1 and S1P receptor 2 and elevated levels of S1P receptor 3.

87 endothelial transmigration by activating the S1P receptor 3.

88 sed to NO production, an effect dependent on S1P-receptor 3 signaling.

89 (S1P), ERK1/2 and matriptase activation via S1P receptor 4 (S1PR4).

90 osine-1-phosphate (S1P) gradients, sensed by S1P receptor 5 (S1P5).

91 n of S1P on sickling that was independent of S1P receptor activation in isolated erythrocytes.

92 S1P transporter spinster homolog 2 (SPNS2), S1P receptor activation, JAK2/STAT3-dependent miR-181b-1

93 ve response of glial cells to PAR-1, LPA, or S1P receptor activation, suggesting that each of these p

94 dies represent the first characterization of S1P receptor activity through G proteins directly and es

95 id cyclohexane ring without compromising the S1P receptor affinity profile of these novel compounds.

96 s for rapidly regulating thymic export where S1P receptor agonism alters both phenotypic maturation a

97 augmentation of Th17 cell development by the S1P receptor agonist and down-regulator FTY720 implies t

98 We have shown previously that the S1P receptor agonist fingolimod (FTY720) attenuates psyc

99 harmacologic treatment with the nonselective S1P receptor agonist FTY720 causes increased bone format

100 Treatment with the S1P receptor agonist FTY720 emptied the cortical sinusoi

101 f phagocytes within peripheral LNs using the S1P receptor agonist FTY720 or S1P1-specific agonist SEW

102 Indeed, an S1P receptor agonist is undergoing clinical trials to co

103 of fingolimod was found to be a nonselective S1P receptor agonist, agonism specifically of S1P1 is re

104 In particular, FTY720, a pan-S1P receptor agonist, has been efficacious in the treatm

105 The sphingosine-1-phosphate (S1P) receptor agonist fingolimod (FTY720), that has show

106 mod, a nonselective sphingosine-1-phosphate (S1P) receptor agonist that induces sustained lymphopenia

107 ) is a nonselective sphingosine-1-phosphate (S1P) receptor agonist thought to be devoid of activity a

108 The sphingosine-1-phosphate (S1P) receptor agonist, phosphorylated FTY720 (FTY-P), ca

109 ch acts as a potent sphingosine-1-phosphate (S1P) receptor agonist.

110 of CD69 induced by sphingosine 1-phosphate (S1P) receptor agonist.

111 The S1P receptor agonists FTY720 and FTY720-phosphate and th

112 S1P receptor agonists induced emptying of lymphoid sinus

113 this model to work examining the effects of S1P receptor agonists on endothelium.

114 of lymphocyte recirculation by non-selective S1P receptor agonists produces clinical immunosuppressio

115 The recent development of S1P receptor agonists, led by the immunomodulatory pro-d

116 e MLN cells harvested from mice treated with S1P receptor agonists, we saw a redistribution of lympho

117 Sphingosine-1-phosphate (S1P) receptor agonists are novel immunosuppressive agent

118 Dihydro-S1P, which binds to S1P receptors, also stimulated contractility.

119 ed mutations affecting genes that encode the S1P receptor and 2 small GTPases (GNA13 and GNAI2) that

120 phingolipid that activates G protein-coupled S1P receptors and initiates a broad range of responses i

121 rstanding of how FTY720, a drug that targets S1P receptors and is approved for the treatment of multi

122 Here, we report that the S1P receptors and metabolic enzymes are conserved in the

123 S1P receptors and metabolizing enzymes have been deleted

124 lecule for studying the molecular biology of S1P receptors and related enzymes (kinases and phosphata

125 n effect and that cell origin determines the S1P receptors and signaling routes involved.

126 on of S1P, which leads to transactivation of S1P receptors and their downstream signaling pathways, r

127 functions through extracellular ligation to S1P receptors, and it also functions as an intracellular

128 There are 5 known S1P receptors, and S1P induces adherens junction formati

129 S1P signaling and provide leads for further S1P receptor antagonist development.

130 Recently, a pharmacological S1P receptor antagonist has won approval to control auto

131 which was partially rescued by VPC23109, an S1P receptor antagonist.

132 S1P receptor antagonists failed to prevent histamine-ind

133 ed arteries using native and S1P-loaded HDL, S1P receptor antagonists, and S1P-blocking antibodies.

134 Subtype-specific S1P receptor antibodies revealed that the expression of

135 S1P receptors are a highly promising target in stroke tr

136 Various S1P receptors are present in the cardiovascular system,

137 Because S1P receptors are therapeutically interesting, identifyi

138 Sphingosine-1-phosphate (S1P) receptors are critical for lymphocyte egress from s

139 been shown that the sphingosine 1 phosphate (S1P) receptors are the direct molecular targets of FTY72

140 o studies and highlight the potential use of S1P receptors as drug targets for treatment of Krabbe's

141 pertussis toxin, an inhibitor of Gi-coupled S1P receptors, as well as antagonists of the S1P recepto

142 we show for the first time that the S1P/SPL/S1P-receptor axis regulates the expression of a number o

143 ot mediated through cell surface Gi -coupled S1P receptors, because none of these responses were inhi

144 mil encodes Edg5, a sphingosine-1-phosphate (S1P) receptor belonging to a family of five G-protein-co

145 Recent information on S1P receptor biology suggests potential utility in the c

146 nduced colocalization of S1P(1) (promotility S1P receptor) but not S1P(2), with SphK1 and FLNa at mem

147 show that functional antagonism of vascular S1P receptors by FTY720 potently inhibits angiogenesis;

148 Thus, differential transactivation of S1P receptors by NGF regulates antagonistic signaling pa

149 desensitization of Sphingosine-1-phosphate (S1P) receptors by FTY720 as well as disruption of S1P gr

150 Although S1P receptors can regulate lymphoid development and lymp

151 sychoactive ingredient in marijuana, whereas S1P receptors contribute to the immunosuppressant effect

152 vity on S1P1 while sparing activity on other S1P receptors could offer equivalent efficacy with reduc

153 aberrant S1P receptor signaling, and lack of S1P receptor coupling to G proteins.

154 human umbilical vein endothelial cells in a S1P receptor-dependent manner.

155 t that a complex interplay between PDGFR and S1P receptors determines their functions.

156 The distribution and function of S1P receptors differ in SSc and healthy fibroblasts, sug

157 the expression of S1P regulatory enzymes and S1P receptors during cardiac development.

158 hepatoma cells stably transfected with human S1P receptor Edg3 or Edg5, which was attributable to sti

159 ist) and dihydro-S1P (potent agonist for all S1P receptors except S1P2) were poor contractile agents.

160 FTY720-P, an S1P analogue that binds all S1P receptors except S1P2, did not inhibit glioblastoma

161 ressant FTY720-phosphate, an agonist for all S1P receptors except S1P2, had distinct contractile prop

162 tiation gene family sphingosine 1-phosphate (S1P) receptors except S1P receptor subtype 2 (S1P(2)).

163 We conclude that S1P receptors expressed by neuroglia are involved in reg

164 e expression of the sphingosine-1-phosphate (S1P) receptors expressed by MZ B cells and/or increased

165 We also demonstrate that S1P receptor expression is deregulated in primary OSCCs

166 Modulation of S1P receptor expression profiles, and of enzymes involve

167 he present study, the effects of S1P and EDG/S1P receptor expression were determined in rat VSM from

168 Given the ubiquity of SK and S1P receptor expression, S1P receptor transactivation ma

169 Activation of CD4 T cells, which decreases S1P receptor expression, suppressed effects of S1P on ch

170 Many of the S1P effects are mediated through S1P receptor family members (S1P(1-5)).

171 igand for G-protein-coupled receptors of the S1P receptor family, regulating diverse biological proce

172 nodes in a CD62L-dependent way and relied on S1P receptors for their exit.

173 Immunoprecipitation of S1P receptors from CEM fractions revealed complexes cont

174 ycling to the cell surface, and desensitized S1P receptor function.

175 0 was independent of its phosphorylation and S1P receptor functions.

176 membrane-associated SphK1 activity, restored S1P receptor functions.

177 ussis toxin (PTX) treatment, consistent with S1P receptor/G(i) protein coupling.

178 re we show that the sphingosine-1-phosphate (S1P) receptor Gpr6 is selectively expressed in the stria

179 The S1P receptors have a novel N-terminal fold that occludes

180 Five S1P receptors have been identified in mammals: LP(B1)/ED

181 ory functions in the apparent absence of EDG S1P receptor homologues.

182 e involved in activating a G protein-coupled S1P receptor important for EGF-directed migration.

183 e also showed that S1P(5) is the predominant S1P receptor in leukemic LGLs, whereas S1P(1) is down-re

184 of this study was to investigate the role of S1P receptors in a non-T-cell model of demyelination, th

185 However, the role of S1P receptors in normal immune cell trafficking is uncle

186 cells (VSMCs), the functions of the specific S1P receptors in the latter cell type are not known.

187 S1P receptors in the vascular system have been character

188 Modulation of sphingosine 1-phosphate (S1P) receptors in a non-selective manner decreases disea

189 ion and function of sphingosine-1-phosphate (S1P) receptors in human thymocyte egress.

190 d/or S1P may regulate calcium channels in an S1P receptor-independent manner.

191 S1P exerts its effects in S1P receptor-independent manner.

192 Structural modeling of the S1P receptors indicated that only S1P(2) can accommodate

193 signaling pathways of glial PAR-1, LPA, and S1P receptors indicates that each receptor class activat

194 Small molecule drugs that downregulate S1P receptors induce the sequestration of lymphocytes wi

195 a drug that targets sphingosine 1-phosphate (S1P) receptors, induced marginal zone B cell migration i

196 Recently, the sphingosine-1-phosphate (S1P) receptor inhibitor FTY720 (also known as Fingolimod

197 and confocal microscopy were used to detect S1P receptors, interleukin (IL) 1R, IL17RA, and nitrosat

198 s, we found that IGF-1 and IGF-2 induced GFP-S1P receptor internalization and that the effect was blo

199 sponding glutamate residue, conserved in all S1P receptors, ion pairs with the S1P ammonium.

200 The expression and localization of S1P receptors is dynamically regulated and controls vasc

201 Distribution of S1P receptor isoforms was altered in SSc fibroblasts, wh

202 sing mouse embryonic fibroblasts (MEFs) from S1P receptor knockout mice, we show here that S1P3 was r

203 20, is a ligand for sphingosine 1-phosphate (S1P) receptors led to studies demonstrating that S1P rec

204 Bioinformatic analysis identified seven S1P receptor-like sequences in the zebrafish genome, inc

205 G2 transporters and consequent activation of S1P receptors may contribute to nongenomic signaling of

206 of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immun

207 Mutations in the zebrafish gene encoding the S1P receptor Miles Apart (Mil)/S1P(2) disrupt the format

208 the spleen and bone marrow, suggesting that S1P receptor modulation restricts egress from hematopoie

209 lation of AAL-R and sphingosine 1-phosphate (S1P) receptor modulation in lungs is essential for immun

210 Ozanimod, another S1P receptor modulator in the approval stage that also t

211 he safety and efficacy of the oral selective S1P receptor modulator ozanimod in patients with relapsi

212 limod (FTY720) is a sphingosine 1-phosphate (S1P) receptor modulator that regulates lymphocyte traffi

213 ration of FTY720, a sphingosine 1-phosphate (S1P) receptor modulator, to db/db mice normalizes fastin

214 h in naive and inflammatory conditions, with S1P receptor modulators FTY720 and BAF312.

215 ional insights on the mechanism of action of S1P receptor modulators in disease.

216 We demonstrate that S1P receptor modulators reduce circulating monocytes in

217 e egress from secondary lymphoid organs, and S1P receptor modulators suppress lymphocyte circulation.

218 receptors, we examined embryos with multiple S1P receptor mutations.

219 The sustained bradycardia induced by S1P receptor non-selective immunosuppressive agonists in

220 tely prevented ERK1/2 activation mediated by S1P receptors, not only reduced migration toward S1P but

221 However, multiple leukocyte subsets express S1P receptors of varying types, and although it is benef

222 S1P-R1 was the prevalent S1P receptor on mature human thymocytes (CD3(hi)CD27(+)C

223 as well as for the biologic functions of the S1P receptors on cells that are circulating in the blood

224 These data reveal a novel role for S1P receptors on monocytes and offer additional insights

225 However, the role of S1P receptors on monocytes is less clear.

226 duced internalization and desensitization of S1P receptors on the surface of mast cells as determined

227 LPA) receptors, and sphingosine-1-phosphate (S1P) receptors on murine astrocytes.

228 alogs induce immunosuppression by modulating S1P receptors other than S1P(1) or S1P(2) on dendritic c

229 The interaction of S1P with the S1P receptors plays a fundamental physiological role in

230 lts highlight the relevance of chemokine and S1P receptor recycling in CLL pathogenesis and clinical

231 , which suggests that discrete mechanisms of S1P receptor regulation are responsible for the efficacy

232 study, we show that expression of S1P1, the S1P receptor responsible for lymphocyte egress, is selec

233 SHEP1 association is required for the BCR or S1P receptor(s) to induce the conversion of CasL into it

234 embryo proper, yolk sac, and allantois, the S1P receptor S1P(2) is expressed in conjunction with S1P

235 ell traffic and proliferation through type 1 S1P receptor (S1P(1)) signals, but suppression of IFN-ga

236 Lymphocyte type 1 S1P receptor (S1P(1)) that transduces S1P chemotactic st

237 RT-PCR revealed that four of the five known S1P receptors (S1P(1-4)) are also expressed in the devel

238 We aimed to determine whether S1P receptors (S1P-Rs) play a role in mature human thymo

239 l differential CD44 isoform interaction with S1P receptors, S1P receptor transactivation, and RhoA/Ra

240 ediator through binding to 5 highly specific S1P receptors, S1P(1-5).

241 ma membrane and differentially activates the S1P receptors S1P1 and S1P2 in a SphK1-dependent manner,

242 Although detrusor expresses the S1P receptors S1P1 and S1P2, only S1P2 appeared to be in

243 recruitment (1 microM, 5 min) to CEMs of the S1P receptors S1P1 and S1P3, p110 PI3 kinase alpha and b

244 Cultured NPCs expressed transcripts for S1P receptors S1P1, S1P2, S1P3, S1P4, and S1P5.

245 P) signaling on targeted cells that bear the S1P receptors S1P1, S1P3, S1P4, and S1P5.

246 king, including the sphingosine-1-phosphate (S1P) receptor S1P1, CD62L and beta7 integrin.

247 ice whose haematopoietic cells lack a single S1P receptor (S1P1; also known as Edg1) there are no T c

248 led lpA receptors (LPA1, LPA2, and LPA3) and s1p receptors (S1P1, S1P2, S1P3, S1P4, and S1P5), collec

249 of HDL-S1P are dependent on signaling by the S1P receptor, S1P1, and involve persistent activation of

250 transporter, spinster homolog 2 (Spns2), and S1P receptor, S1P1, in lamellipodia formation and perhap

251 S1P receptors, as well as antagonists of the S1P receptor, S1P1, inhibited barrier enhancement by HDL

252 Although the S1P receptors (S1P1R, S1P2R, and S1P3R) are expressed, p

253 Here, we show that two S1P receptors, S1P2 and S1P3, are collectively essential

254 Two S1P receptors, S1P2 and S1P3, were found to be expressed

255 l phenotype is normalized by deletion of the S1P receptor S1P3.

256 d the induction of fibrotic responses by the S1P receptor (S1PR) agonists S1P, FTY720-P, ponesimod, a

257 This inhibition is mediated by the S1P receptor (S1PR)-2 via an inhibitory G-dependent mech

258 ed the potential of sphingosine 1-phosphate (S1P) receptor (S1PR) agonism in the treatment of infecti

259 Correspondingly, mice lacking the S1P receptor S1pr1 develop severe thrombocytopenia cause

260 1 (SphK1(-/-)) or with reduced expression of S1P receptors (S1PR1(+/-), S1PR2(-/-), and S1PR3(-/-)) e

261 or STAT3, and consequent upregulation of the S1P receptor, S1PR1.

262 Rather, two S1P receptors, S1PR1 and S1PR2, coordinately promoted mi

263 Mice lacking the S1P receptor S1PR2 also showed a delay in plasma histami

264 mediated at least in part by ligation of the S1P receptor, S1PR2.

265 g nodose neurons express mRNA coding for the S1P receptor S1PR3.

266 C-fibre neurons express mRNA coding for the S1P receptor S1PR3.

267 that expression of SPNS2, expression of the S1P receptor S1PR5 on NK cells, and expression of the ch

268 and Gbetagamma subunits, the G proteins that S1P receptors (S1PRs) couple to and signal through.

269 atory fluids, and binds to G protein-coupled S1P receptors (S1PRs) to regulate embryonic development,

270 S1P regulates diverse cell activities via S1P receptors (S1PRs).

271 tor of G protein signaling 3, which inhibits S1P receptor signaling and completely prevented ERK1/2 a

272 n many types of neurodegeneration, the Sphk1/S1P receptor signaling axis may be generally important d

273 This work establishes a role for S1P receptor signaling in the local conditioning of tiss

274 ion in S1P lyase-deficient mice, implicating S1P receptor signaling in the phenotype.

275 ocal immunofluorescence microscopy, aberrant S1P receptor signaling, and lack of S1P receptor couplin

276 some key physiologic processes that require S1P receptor signaling, such as vascular development and

277 The sphingosine-1-phosphate (S1P) receptor signaling system has biological and medica

278 The sphingosine 1-phosphate (S1P) receptor signaling system is a productive model sys

279 (iNOS) expression, sphingosine 1 phosphate (S1P) receptor status, and apoptosis.

280 orn that corresponded with the engagement of S1P receptor subtype 1 (S1PR(1))- dependent neuroinflamm

281 uropathic pain by selectively activating the S1P receptor subtype 1 (S1PR1) in astrocytes.

282 hingosine 1-phosphate (S1P) receptors except S1P receptor subtype 2 (S1P(2)).

283 adenocarcinoma cell lines abundantly express S1P receptor subtype 3 (S1P3), thus providing a tractabl

284 ing proteases and selectivity in coupling to S1P receptor subtypes determine vascular PAR1 signaling

285 ignaling may be related to the expression of S1P receptor subtypes.

286 reported expression and in vitro studies of S1P receptors suggested that direct CNS effects of FTY72

287 he action of SK2, with signaling mediated by S1P receptors that include S1P(1), S1P(2), and S1P(3).

288 ed by chemokine and sphingosine 1-phosphate (S1P) receptors that enable homing and egress from second

289 nvironment and signals via G protein-coupled S1P receptors to regulate cell-cell and cell-matrix adhe

290 that extracellular S1P acts through vascular S1P receptors to regulate vascular development.

291 points regulated by constitutive and induced S1P receptor tone at vascular endothelial and lymphatic

292 ubiquity of SK and S1P receptor expression, S1P receptor transactivation may represent a general mec

293 CD44 isoform interaction with S1P receptors, S1P receptor transactivation, and RhoA/Rac1 signaling to

294 receptors led to studies demonstrating that S1P receptor type 1 (S1P1) is needed in T cells and B ce

295 Here we report that sphingosine 1-phosphate (S1P) receptor type 1 (S1P1) delivers an intrinsic negati

296 functions of the two other widely expressed S1P receptors, we generated S1P(2) and S1P(3) null mice.

297 ndent of effects on sphingosine-1-phosphate (S1P) receptors, we embarked on the pharmacological explo

298 The wild-type and mutant S1P receptors were expressed in Chinese hamster ovary ce

299 by RNA interference, and blocking endogenous S1P receptors with the competitive antagonist VPC23019 a

300 Furthermore, activation of S1P receptors with their natural ligand, S1P, as well as